The Drug Discovery Programme at the Beatson Institute for Cancer Research has a number of targets including:…
1 c-Myc – a hub transcription factor which regulates many important processes in the development of cancer. Many upstream and downstream oncogenes are regulated through Myc and it therefore represents an attractive pleiotropic target for the treatment of cancer.
2 RAS – RAS mutations may be one of the initiating mutations in many cancers. They are found in up to 30 per cent of human cancers and are particularly common in pancreatic, colon and lung adenocarcinoma. It is one of the most challenging “undruggable” targets in cancer research.